Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
53 hedge funds and large institutions have $33.5M invested in Syros Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 10 closing their positions.
82,700% more call options, than puts
Call options by funds: $828K | Put options by funds: $1K
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
22% more capital invested
Capital invested by funds: $27.5M → $33.5M (+$5.96M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 59 → 53 (-6)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$1.8M |
| 2 |
DMKJ
David M. Knott Jr
|
+$309K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$150K |
| 4 |
BlackRock
New York
|
+$73.6K |
| 5 |
SC
Shay Capital
New York
|
+$39.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
-$665K |
| 2 |
Millennium Management
New York
|
-$211K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$81.6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$63.1K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$58.5K |
SYRS Hedge Fund Activity: Q2 2023 in Review
53 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2023, worth a combined $33.5M — up 22% from $27.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SYRS and 4 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 12 added.
The largest buyer was Avidity Partners Management, adding an estimated $1.8M. The largest seller was Ally Bridge Group, exiting entirely with an estimated $665K sold.
- 53 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2023, down from 59 in Q1 2023.
- Funds reported $33.5M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2023, up 22% quarter-over-quarter.
- 4 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 10 closed out, a net change of -6 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was Avidity Partners Management, an estimated $1.8M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Ally Bridge Group, an estimated $665K sold.
Based on aggregated 13F filings for Q2 2023.